Kaleido Biosciences Announces Appointment of Katharine Knobil as Chief Medical Officer and Head of Research & Development
December 03, 2018 at 09:00 am EST
Kaleido Biosciences announced the appointment of Katharine Knobil, M.D. as chief medical officer and head of research and development. Dr. Knobil joins Kaleido from GlaxoSmithKline (GSK), where she most recently served as CMO, and spent more than 20 years in roles of increasing responsibility in clinical development, health outcomes and medical affairs. She will report to Kaleido’s chief executive officer, Alison Lawton.